The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...

The National Kidney Foundation (NKF) has awarded Roger Rodby, MD, Professor of Medicine, Division of Nephrology at Rush University Medical Center, the Donald W. Seldin Award.  The distinguished honor ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

A few bubbles in your pee is normal, but foamy urine could require a trip to the doctor for a diagnosis and prescription.

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

adding a mid-stage drug candidate for kidney disease IgA nephropathy (IgAN). The $65-per-share deal is due to close within the next three months, said Vertex, which plans to fund the acquisition ...